Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Medexus Pharmaceuticals Inc. (V:MDP)

Business Focus: Pharmaceuticals

INK Edge Outlook

Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for MDP within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 19, 2019 08:30 ET
Medexus Reports Annual Meeting Results
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) announces voting results from its Annual Meeting of Shareholders held on September 18, 2019 in Toronto, Ontario (the “Meeting”). A total of 5,228,034 Common...
Read full article
Sep 12, 2019 08:30 ET
Medexus Reports Health Quality Ontario Recommends Gliolan® for Public Reimbursement
Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that Health Quality Ontario, under the guidance of the Ontario Health Technology Advisory Committee, has recommended public  funding of Gliolan®...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.33
--
--
Price to Sales - TTM
1.37
5.28
12.99
Price to Book - most recent quarter
1.89
2.62
2.71
Price to Cash Flow per share - TTM
--
6.75
12.05
Price to Free Cash Flow per share - TTM
--
9.60
17.60
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Sep 15, 20191,947900
Aug 31, 20191,047-6,596
Aug 15, 20197,6437,148
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc, is a Canada-based company engaged in pharmaceutical business sector. The Company is a North American focused, specialty pharmaceutical business that operates through three segments: Medac Pharma USA, a fully integrated commercial infrastructure focused on auto-immune diseases in the United States; Medexus Pharma Canada, a fully integrated commercial infrastructure focused on auto-immune disease and pediatric diseases in Canada; and a Business Development function, which works to maintain its product pipeline. The Company's flag products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an allergy medication. The Company provides products for the healthcare professionals and patients.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $MDP.CA MDP.V